Surgical Endoscopy

, Volume 24, Issue 8, pp 1866–1871 | Cite as

Preoperative infliximab treatment and postoperative complications after laparoscopic restorative proctocolectomy with ileal pouch–anal anastomosis: a case-matched study

  • Benjamin Coquet-Reinier
  • Stéphane V. Berdah
  • Jean-Charles Grimaud
  • David Birnbaum
  • Pierre-Alain Cougard
  • Marc Barthet
  • Ariadne Desjeux
  • Vincent Moutardier
  • Christian Brunet
Article

Abstract

Background

Infliximab offers promising new therapeutic options for treatment of moderate to severe ulcerative colitis. However, several studies suggest that it increases postoperative complication rates for patients who later require a restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA). This study aimed to assess the postoperative course of patients after laparoscopic IPAA, comparing those who had and those who had not received infliximab before surgery.

Methods

The authors identified patients from their institution’s IPAA database, finding 13 patients who had received preoperative infliximab treatment. Using age, gender, and type of procedure (2 or 3 stages) as criteria, they matched these cases with infliximab-naive patients drawn from the same database. The differences in perioperative data between the two groups were analyzed. Complications and their severity were assessed using the Strasberg classification.

Results

No significant difference was found between patients treated with and those treated without infliximab for each variable studied, namely, mean operative time (353 vs. 355 min), complication rate (23 vs. 38%), and mean hospital stay (22 vs. 25 days).

Conclusion

The study findings showed no adverse impact from previous infliximab therapy on the laparoscopic IPAA postoperative course.

Keywords

Complications Ileal pouch anal anastomosis Infliximab Laparoscopy Ulcerative colitis 

References

  1. 1.
    Chey WY (2001) Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 7(Suppl 1):S30–S33CrossRefPubMedGoogle Scholar
  2. 2.
    Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M (2002) Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis 34:626–630CrossRefPubMedGoogle Scholar
  3. 3.
    Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, Stein RB, Adler DR, Lichtenstein GR (2002) Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 97:2577–2584CrossRefPubMedGoogle Scholar
  4. 4.
    Rutgeerts P, Sandborn WJ, Feagan BG (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476CrossRefPubMedGoogle Scholar
  5. 5.
    Aratari A, Papi C, Clemente V, Moretti A, Luchetti R, Koch M, Capurso L, Caprilli R (2008) Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis 40:821–826CrossRefPubMedGoogle Scholar
  6. 6.
    Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ (2004) Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 99:878–883CrossRefPubMedGoogle Scholar
  7. 7.
    Gaertner WB, Decanini A, Mellgren A, Lowry AC, Goldberg SM, Madoff RD, Spencer MP (2007) Does infliximab infusion impact results of operative treatment for Crohn’s perianal fistulas? Dis Colon Rectum 50:1754–1760CrossRefPubMedGoogle Scholar
  8. 8.
    Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH (2008) Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 51:1202–1297; discussion 1207–1210CrossRefPubMedGoogle Scholar
  9. 9.
    Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Loftus EV Jr, Sandborn WJ, Wolff BG, Pemberton JH (2007) Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 204:956–962; discussion 962–963CrossRefPubMedGoogle Scholar
  10. 10.
    Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L (2008) Perioperative treatment with infliximab in patients with Crohn’s disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 12:1730–1736CrossRefPubMedGoogle Scholar
  11. 11.
    Schluender SJ, Ippoliti A, Dubinsky M, Vasiliauskas EA, Papadakis KA, Mei L, Targan SR, Fleshner PR (2007) Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis. Dis Colon Rectum 50:1747–1753CrossRefPubMedGoogle Scholar
  12. 12.
    Ferrante M, D’Hoore A, Vermeire S, Declerck S, Noman M, Van Assche G, Hoffman I, Rutgeerts P, Penninckx F (2009) Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 15:1062–1070CrossRefPubMedGoogle Scholar
  13. 13.
    Fazio VW, Ziv Y, Church JM (1995) Ileal pouch–anal anastomosis complications and function in 1005 patients. Ann Surg 222:120–127CrossRefPubMedGoogle Scholar
  14. 14.
    Ahmed Ali U, Keus F, Heikens JT, Bemelman WA, Berdah SV, Gooszen HG, van Laarhoven CJ (2009) Open versus laparoscopic (assisted) ileo pouch anal anastomosis for ulcerative colitis and familial adenomatous polyposis. Cochrane Database Syst Rev. doi:10.1002/14651858
  15. 15.
    Berdah SV, Barthet M, Emungania O, Orsoni P, Alliot P, Grimaud JC, Brunet C (2004) Coloproctectomie totale avec anastomose iléoanale en deux temps vidéoassistée. Expérience initiale de 12 cas. Ann Chir 129:332–336CrossRefPubMedGoogle Scholar
  16. 16.
    Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6,336 patients and results of a survey. Ann Surg 240:205–213CrossRefPubMedGoogle Scholar
  17. 17.
    Shih DQ, Targan SR (2008) Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 14:390–400CrossRefPubMedGoogle Scholar
  18. 18.
    Chey WY, Hussain A, Ryan C, Potter GD, Shah A (2001) Infliximab for refractory ulcerative colitis. Am J Gastroenterol 96:2373–2381CrossRefPubMedGoogle Scholar
  19. 19.
    Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan H, Hellstrom PM, Magnuson A, Curman B (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128:1805–1811CrossRefPubMedGoogle Scholar
  20. 20.
    Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT (1993) Location of tumor necrosis factor alpha by immunochemistry in chronic inflammatory bowel disease. Gut 34:1705–1709CrossRefPubMedGoogle Scholar
  21. 21.
    Reinecker HC, Steffen M, Witthoett T (1993) Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1-beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol 94:174–181PubMedCrossRefGoogle Scholar
  22. 22.
    Scallon BJ, Moore MA, Trinth H (1995) Chimeric anti-TNF-alpha monoclonal antibody CA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7:251–259CrossRefPubMedGoogle Scholar
  23. 23.
    Schmidt M, Luegering N, Luegering A (2000) Infliximab exerts antiinflammatory capacity in IBD by induction of apoptosis in monocytes. Gastroenterology 118:3630Google Scholar
  24. 24.
    Albina J, Mastrofrancesco B, Vessella J (2001) HIF-1 expression in healing wounds: HIF-1alpha induction in primary inflammatory cells by TNF-alpha. Am J Physiol Cell Physiol 281:C1971–C1977PubMedGoogle Scholar
  25. 25.
    Lee L, Efron D, Tantry U (2000) Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats. Wound Rep Reg 8:547–553CrossRefGoogle Scholar
  26. 26.
    Wiese D, Lashner B, Seidner D (2008) Measurement of nutrition status in Crohn’s disease patients receiving infliximab therapy. Nutr Clin Pract 23:551–556CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Benjamin Coquet-Reinier
    • 1
  • Stéphane V. Berdah
    • 1
    • 2
  • Jean-Charles Grimaud
    • 1
  • David Birnbaum
    • 1
  • Pierre-Alain Cougard
    • 1
  • Marc Barthet
    • 1
  • Ariadne Desjeux
    • 1
  • Vincent Moutardier
    • 1
  • Christian Brunet
    • 1
  1. 1.Department of Digestive Diseases SurgeryHôpital NordMarseille Cedex 20France
  2. 2.Université de la MéditerranéeMarseilleFrance

Personalised recommendations